189 related articles for article (PubMed ID: 31574418)
41. [Brachytherapy for anal cancers].
Pommier P; Mirabel X; Hannoun-Lévi JM; Malet C; Gérard JP; Peiffert D
Cancer Radiother; 2013 Apr; 17(2):143-50. PubMed ID: 23582604
[TBL] [Abstract][Full Text] [Related]
42. Treatment of anal carcinoma in the elderly: feasibility and outcome of radical radiotherapy with or without concomitant chemotherapy.
Allal AS; Obradovic M; Laurencet F; Roth AD; Spada A; Marti MC; Kurtz JM
Cancer; 1999 Jan; 85(1):26-31. PubMed ID: 9921970
[TBL] [Abstract][Full Text] [Related]
43. Intensity-modulated Radiotherapy for Anal Cancer: Dose-Volume Relationship of Acute Gastrointestinal Toxicity and Disease Outcomes.
Ng M; Ho H; Skelton J; Guerrieri M; Guiney M; Chao M; Blakey D; Macleod C; Amor H; Subramanian B; Melven L
Clin Oncol (R Coll Radiol); 2018 Oct; 30(10):634-641. PubMed ID: 30049649
[TBL] [Abstract][Full Text] [Related]
44. Intensity-Modulated Radiotherapy (IMRT) vs Helical Tomotherapy (HT) in Concurrent Chemoradiotherapy (CRT) for Patients with Anal Canal Carcinoma (ACC): an analysis of dose distribution and toxicities.
Yeung R; McConnell Y; Warkentin H; Graham D; Warkentin B; Joseph K; Doll CM
Radiat Oncol; 2015 Apr; 10():92. PubMed ID: 25903798
[TBL] [Abstract][Full Text] [Related]
45. [Epidermoid carcinomas of anal canal treated with radiation therapy and concomitant chemotherapy (5-fluorouracil and cisplatin)].
Deniaud-Alexandre E; Touboul E; Tiret E; Sezeur A; Hannoun L; Houry S; Huguet F; Pène F; Parc R; Schlienger M
Cancer Radiother; 2006 Dec; 10(8):572-82. PubMed ID: 17110148
[TBL] [Abstract][Full Text] [Related]
46. Prognostic factors for recurrence and survival in anal cancer: generating hypotheses from the mature outcomes of the first United Kingdom Coordinating Committee on Cancer Research Anal Cancer Trial (ACT I).
Glynne-Jones R; Sebag-Montefiore D; Adams R; Gollins S; Harrison M; Meadows HM; Jitlal M;
Cancer; 2013 Feb; 119(4):748-55. PubMed ID: 23011911
[TBL] [Abstract][Full Text] [Related]
47. Significance of Co-expression of Epidermal Growth Factor Receptor and Ki67 on Clinical Outcome in Patients With Anal Cancer Treated With Chemoradiotherapy: An Analysis of NRG Oncology RTOG 9811.
Doll CM; Moughan J; Klimowicz A; Ho CK; Kornaga EN; Lees-Miller SP; Ajani JA; Crane CH; Kachnic LA; Okawara GS; Berk LB; Roof KS; Becker MJ; Grisell DL; Ellis RJ; Sperduto PW; Marsa GW; Guha C; Magliocco AM
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):554-562. PubMed ID: 28126304
[TBL] [Abstract][Full Text] [Related]
48. Haematotoxicity in IMRT/VMAT curatively treated anal cancer.
Lohynská R; Nýdlová A; Drbohlavová T; Mazaná E; Jirkovská M; Veselský T; Malinová B; Stankušová H
Klin Onkol; 2020; 33(4):288-294. PubMed ID: 32894958
[TBL] [Abstract][Full Text] [Related]
49. Combined chemoradiation therapy for anal cancer. A report of 56 cases.
Doci R; Zucali R; Bombelli L; Montalto F; Lamonica G
Ann Surg; 1992 Feb; 215(2):150-6. PubMed ID: 1546901
[TBL] [Abstract][Full Text] [Related]
50. Twenty-five-year experience with radical chemoradiation for anal cancer.
Tomaszewski JM; Link E; Leong T; Heriot A; Vazquez M; Chander S; Chu J; Foo M; Lee MT; Lynch CA; Mackay J; Michael M; Tran P; Ngan SY
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):552-8. PubMed ID: 22019078
[TBL] [Abstract][Full Text] [Related]
51. Tumor site predicts outcome after radiochemotherapy in squamous-cell carcinoma of the anal region: long-term results of 101 patients.
Grabenbauer GG; Kessler H; Matzel KE; Sauer R; Hohenberger W; Schneider IH
Dis Colon Rectum; 2005 Sep; 48(9):1742-51. PubMed ID: 15991058
[TBL] [Abstract][Full Text] [Related]
52. Toxicity, Tolerability, and Compliance of Concurrent Capecitabine or 5-Fluorouracil in Radical Management of Anal Cancer With Single-dose Mitomycin-C and Intensity Modulated Radiation Therapy: Evaluation of a National Cohort.
Jones CM; Adams R; Downing A; Glynne-Jones R; Harrison M; Hawkins M; Sebag-Montefiore D; Gilbert DC; Muirhead R
Int J Radiat Oncol Biol Phys; 2018 Aug; 101(5):1202-1211. PubMed ID: 29859793
[TBL] [Abstract][Full Text] [Related]
53. Anal cancer chemoirradiation with curative intent - a single institution experience.
Oblak I; Petric P; Anderluh F; Velenik V; Hudej R; Fras AP
Neoplasma; 2009; 56(2):150-5. PubMed ID: 19239330
[TBL] [Abstract][Full Text] [Related]
54. Evolution and Management of Treatment-Related Toxicity in Anal Cancer.
Ludmir EB; Kachnic LA; Czito BG
Surg Oncol Clin N Am; 2017 Jan; 26(1):91-113. PubMed ID: 27889040
[TBL] [Abstract][Full Text] [Related]
55. Three cytotoxic drugs combined with pelvic radiation and as maintenance chemotherapy for patients with squamous cell carcinoma of the anus (SCCA): long-term follow-up of a phase II pilot study using 5-fluorouracil, mitomycin C and cisplatin.
Sebag-Montefiore D; Meadows HM; Cunningham D; Plowman PN; Hurman DC; Davidson N; Grieve R; Levine E; Glynne-Jones R
Radiother Oncol; 2012 Aug; 104(2):155-60. PubMed ID: 22857859
[TBL] [Abstract][Full Text] [Related]
56. [Radiochemotherapy in anal canal epidermoid cancer].
Peiffert D
Ann Chir; 2000 Oct; 125(8):717-25. PubMed ID: 11105342
[TBL] [Abstract][Full Text] [Related]
57. Long-Term Outcomes of NRG Oncology/RTOG 0529: A Phase 2 Evaluation of Dose-Painted Intensity Modulated Radiation Therapy in Combination With 5-Fluorouracil and Mitomycin-C for the Reduction of Acute Morbidity in Anal Canal Cancer.
Kachnic LA; Winter KA; Myerson RJ; Goodyear MD; Abitbol AA; Streeter OE; Augspurger ME; Schefter TE; Katz AW; Fisher BJ; Henke LE; Narayan S; Crane CH
Int J Radiat Oncol Biol Phys; 2022 Jan; 112(1):146-157. PubMed ID: 34400269
[TBL] [Abstract][Full Text] [Related]
58. Are there HIV-specific Differences for Anal Cancer Patients Treated with Standard Chemoradiotherapy in the Era of Combined Antiretroviral Therapy?
Martin D; Balermpas P; Fokas E; Rödel C; Yildirim M
Clin Oncol (R Coll Radiol); 2017 Apr; 29(4):248-255. PubMed ID: 28049602
[TBL] [Abstract][Full Text] [Related]
59. Impact of compliance to chemoradiation on long-term outcomes in squamous cell carcinoma of the anus: results of a post hoc analysis from the randomised phase III ACT II trial.
Glynne-Jones R; Meadows HM; Lopes A; Muirhead R; Sebag-Montefiore D; Adams R;
Ann Oncol; 2020 Oct; 31(10):1376-1385. PubMed ID: 32619648
[TBL] [Abstract][Full Text] [Related]
60. VITAL phase 2 study: Upfront 5-fluorouracil, mitomycin-C, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal canal (GEMCAD 09-02).
Feliu J; Garcia-Carbonero R; Capdevila J; Guasch I; Alonso-Orduna V; Lopez C; Garcia-Alfonso P; Castanon C; Sevilla I; Cerezo L; Conill C; Quintana-Angel B; Sanchez ME; Ghanem I; Martin-Richard M; Lopez-Gomez M; Leon A; Caro M; Fernandez T; Maurel J
Cancer Med; 2020 Feb; 9(3):1008-1016. PubMed ID: 31851776
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
